Your browser is no longer supported. Please, upgrade your browser.
WVE Wave Life Sciences Ltd. daily Stock Chart
Wave Life Sciences Ltd.
Index- P/E- EPS (ttm)-5.66 Insider Own0.60% Shs Outstand35.21M Perf Week-9.30%
Market Cap363.68M Forward P/E- EPS next Y-1.66 Insider Trans-50.87% Shs Float16.88M Perf Month-44.92%
Income-195.50M PEG- EPS next Q-0.69 Inst Own67.90% Short Float31.80% Perf Quarter-15.75%
Sales12.50M P/S29.09 EPS this Y-12.90% Inst Trans-0.02% Short Ratio4.62 Perf Half Y5.34%
Book/sh-0.13 P/B- EPS next Y54.10% ROA-72.80% Target Price- Perf Year-61.64%
Cash/sh2.14 P/C3.86 EPS next 5Y- ROE-401.30% 52W Range6.61 - 39.98 Perf YTD3.43%
Dividend- P/FCF- EPS past 5Y- ROI-327.00% 52W High-79.26% Beta0.32
Dividend %- Quick Ratio1.30 Sales past 5Y- Gross Margin- 52W Low25.42% ATR1.12
Employees301 Current Ratio1.30 Sales Q/Q-60.50% Oper. Margin- RSI (14)38.05 Volatility5.50% 8.03%
OptionableYes Debt/Eq- EPS Q/Q6.00% Profit Margin- Rel Volume0.45 Prev Close8.41
ShortableYes LT Debt/Eq- EarningsAug 10 BMO Payout- Avg Volume1.16M Price8.29
Recom2.10 SMA20-10.15% SMA50-25.48% SMA200-13.63% Volume518,476 Change-1.43%
Dec-31-19Downgrade SVB Leerink Outperform → Mkt Perform $33 → $10
Nov-01-19Initiated Guggenheim Buy $43
Jul-15-19Initiated Cowen Market Perform
Apr-17-19Reiterated H.C. Wainwright Buy $49 → $33
Aug-07-18Initiated Stifel Buy $56
Jul-23-18Initiated H.C. Wainwright Buy $49
Mar-19-18Reiterated Mizuho Buy $34 → $65
Feb-15-17Initiated H.C. Wainwright Buy $41
Nov-10-16Resumed Leerink Partners Outperform
Dec-07-15Initiated Sun Trust Rbsn Humphrey Buy $26
Dec-07-15Initiated Leerink Partners Outperform $20
Dec-07-15Initiated JMP Securities Mkt Outperform $52
Dec-07-15Initiated Jefferies Buy $28
Sep-28-20 04:05PM  
Sep-23-20 10:02AM  
Sep-22-20 04:19PM  
Sep-16-20 09:14AM  
Sep-15-20 08:20AM  
Sep-10-20 04:25PM  
Aug-10-20 09:30PM  
Aug-06-20 08:00AM  
Aug-03-20 12:31PM  
Jul-27-20 04:05PM  
Jun-24-20 08:46AM  
Jun-18-20 05:14PM  
May-26-20 04:05PM  
May-18-20 07:30AM  
May-11-20 07:01PM  
Apr-29-20 04:05PM  
Apr-23-20 07:01PM  
Apr-22-20 06:35PM  
Mar-24-20 10:38AM  
Mar-02-20 07:55AM  
Feb-26-20 11:55AM  
Feb-24-20 12:30PM  
Feb-19-20 08:00AM  
Feb-18-20 08:00AM  
Feb-13-20 08:05AM  
Jan-22-20 11:48AM  
Jan-16-20 09:39AM  
Jan-14-20 09:55AM  
Dec-31-19 06:10AM  
Dec-30-19 04:10PM  
Dec-24-19 12:18PM  
Dec-23-19 09:52AM  
Dec-16-19 04:09PM  
Dec-11-19 02:21PM  
Dec-06-19 02:23PM  
Nov-14-19 10:02AM  
Nov-06-19 12:15PM  
Nov-05-19 07:15PM  
Nov-01-19 10:30AM  
Oct-28-19 02:13PM  
Sep-18-19 02:12PM  
Sep-16-19 07:30AM  
Sep-06-19 08:30AM  
Aug-26-19 04:05PM  
Aug-20-19 12:20PM  
Aug-06-19 07:30AM  
Jul-29-19 07:05PM  
Jul-17-19 03:23PM  
Jul-01-19 09:35AM  
Jun-27-19 08:00AM  
Jun-12-19 08:00AM  
Jun-06-19 06:10PM  
May-10-19 08:45AM  
May-02-19 02:18PM  
May-01-19 10:33AM  
Apr-23-19 12:23PM  
Apr-17-19 11:10AM  
Apr-16-19 05:17PM  
Apr-13-19 09:38AM  
Apr-12-19 08:00AM  
Apr-10-19 11:18AM  
Mar-28-19 10:20AM  
Mar-25-19 08:00AM  
Mar-07-19 02:54PM  
Mar-06-19 08:00AM  
Mar-01-19 07:30AM  
Feb-22-19 07:45AM  
Feb-12-19 01:17PM  
Jan-29-19 02:19PM  
Jan-24-19 12:21PM  
Jan-23-19 04:23PM  
Jan-15-19 06:07AM  
Jan-04-19 11:38AM  
Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces of novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. The company is primarily developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins. It focuses on programs in neurology in the central nervous system and neuromuscular system. The company has a research, license, and option agreement with Pfizer Inc. and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of stereopure oligonucleotide therapeutics and oligonucleotide therapeutics; and research, development, and develop antisense oligonucleotides. Wave Life Sciences Ltd. was founded in 2012 and is based in Singapore.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BOLNO PAULPresident and CEOSep 15Option Exercise2.48100,000248,000372,181Sep 17 09:10 PM
BOLNO PAULPresident and CEOSep 15Sale15.00100,0001,500,000272,181Sep 17 09:10 PM
BOLNO PAULPresident and CEOAug 25Option Exercise2.4825,00062,000297,181Aug 27 06:44 PM
BOLNO PAULPresident and CEOAug 25Sale12.0025,000300,000272,181Aug 27 06:44 PM
BOLNO PAULPresident and CEOJul 02Option Exercise2.48100,000248,000372,181Jul 02 08:56 PM
BOLNO PAULPresident and CEOJul 02Sale10.30147,5771,520,276272,181Jul 02 08:56 PM
Panzara Michael A.Chief Medical OfficerFeb 18Sale7.852,98123,40139,349Feb 20 06:26 PM
BOLNO PAULPresident and CEOFeb 18Sale7.8511,45189,890319,758Feb 20 06:23 PM
Francis ChrisSee RemarksFeb 18Sale7.852,70821,25831,160Feb 20 06:21 PM
Vargeese ChandraSenior VP, Drug DiscoveryFeb 18Sale7.853,18825,02637,057Feb 20 06:18 PM
Gaiero David GInterim CFOFeb 03Sale7.006514,5576,392Feb 05 06:16 PM
Vargeese ChandraSenior VP, Drug DiscoveryDec 03Option Exercise2.486,00014,88046,245Dec 05 06:08 PM
Vargeese ChandraSenior VP, Drug DiscoveryDec 03Sale35.006,000210,00040,245Dec 05 06:08 PM
Verdine Gregory L.DirectorNov 20Sale30.6330,039920,21330,000Nov 22 05:49 PM